CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis

CervoMed Inc. announced that its drug candidate neflamapimod has been selected for inclusion in the UK's EXPERTS-ALS platform, a government-funded clinical trial designed to rapidly test potential ALS treatments. The trial will initially evaluate neflamapimod in approximately 35 ALS patients over 18-24 weeks, with potential expansion to 80 patients. The selection is based on the drug's targeted mechanism of action and positive clinical data in dementia with Lewy bodies trials.

02/18/2026, 6:00 AM • GlobeNewswire

CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies

CervoMed presented Phase 2b trial results showing neflamapimod significantly slows clinical progression in dementia with Lewy bodies, with most prominent improvements in patients without AD co-pathology. The company plans to initiate Phase 3 trials in 2026.

12/04/2025, 5:00 PM • GlobeNewswire

CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)

CervoMed shared Phase 2b trial data showing neflamapimod treatment reduced neuroinflammation biomarkers in Dementia with Lewy Bodies patients, with promising results indicating potential disease progression slowing.

12/02/2025, 7:00 AM • GlobeNewswire

CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

CervoMed will present new data on neflamapimod, a potential treatment for Dementia with Lewy Bodies (DLB), at the 18th Clinical Trials on Alzheimer's Disease Conference, highlighting results from their Phase 2b RewinD-LB trial.

11/24/2025, 7:00 AM • GlobeNewswire

Presenting on Emerging Growth Conference 87 Day 2 on October 23; Register to live stream

EmergingGrowth.com announced the schedule for its 87th conference featuring presentations from multiple small-cap companies across various sectors on October 22-23, 2025, providing insights into emerging growth opportunities.

10/22/2025, 7:00 AM • GlobeNewswire

CervoMed to Present at the Emerging Growth Conference

CervoMed, a clinical-stage company developing treatments for age-related neurologic disorders, will present at the Emerging Growth Conference on October 22, 2025, discussing their investigational drug neflamapimod for treating Dementia with Lewy Bodies.

10/20/2025, 8:00 AM • GlobeNewswire

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

CervoMed, a clinical-stage company developing treatments for neurologic disorders, will participate in the 4th Annual ROTH Healthcare Opportunities Conference in New York on October 9, 2025, presenting on small firms addressing major medical indications.

10/02/2025, 8:00 AM • GlobeNewswire

CervoMed to Participate in Upcoming Investor Conferences

CervoMed, a clinical-stage company developing treatments for neurologic disorders, will participate in the H.C. Wainwright and Morgan Stanley Global Healthcare conferences in September 2025, presenting its investigational drug neflamapimod for Dementia with Lewy Bodies (DLB).

09/03/2025, 8:00 AM • GlobeNewswire

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod’s Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

CervoMed reported positive 32-week trial results for neflamapimod in treating Dementia with Lewy Bodies (DLB), showing a 54% risk reduction in clinical progression and significant reduction in neurodegeneration biomarkers.

07/28/2025, 7:00 AM • GlobeNewswire